Innate Pharma (IPHA) EBIT Margin (2019 - 2025)
Innate Pharma's (IPHA) quarterly EBIT Margin came in at 1876.46% in Q4 2025, down 145303.0% YoY from N/an in Q4 2024, and down 343.15% on a QoQ basis from 423.44% in Q4 2024.
Innate Pharma (IPHA) EBIT Margin (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of EBIT Margin data on file, last reported at 1876.46% in Q4 2025.
- Quarterly EBIT Margin fell 145303.0% year-over-year to 1876.46% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 214.84% (down 13261.0% YoY) and the FY2025 annual result came in at 599.76%, down 34343.0% from the prior year.
- EBIT Margin declined to 1876.46% in Q4 2025, from 423.44% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 0.03% in Q4 2022 to a low of 1876.46% in Q4 2025.
- A 5-year average of 433.05% and a median of 317.29% in 2024 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin jumped 39482 bps — and 2025, when it slumped 145303 bps.
- Tracing IPHA's EBIT Margin over 5 years: stood at 394.86% in 2021, then surged by 100 bps to 0.03% in 2022, then plunged by 54582 bps to 18.12% in 2023, then sank by 2237 bps to 423.44% in 2024, then slumped by 343 bps to 1876.46% in 2025.
- The last three EBIT Margin figures came in at 1876.46% (Q4 2025), 423.44% (Q4 2024), and 317.29% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | -1,876.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,876.46% |
| Dec 31, 2024 | -423.44% |
| Jun 30, 2024 | -317.29% |
| Dec 31, 2023 | -18.12% |
| Jun 30, 2023 | -1.13% |
| Dec 31, 2022 | -0.03% |
| Dec 31, 2021 | -394.86% |
| Dec 31, 2020 | -13.52% |
| Dec 31, 2019 | -37.31% |